Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies-Reference-Cited by-同舟云学术

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

Published:2011-07 Issue:3 Volume:105 Page:353-359
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Eisen T,Marais R,Affolter A,Lorigan P,Robert C,Corrie P,Ottensmeier C,Chevreau C,Chao D,Nathan P D,Jouary T,Harries M,Negrier S,Montegriffo E,Ahmad T,Gibbens I,James M G,Strauss U P,Prendergast S,Gore M E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2011257.pdf

Reference36 articles.

1. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, Kumar R (2005) BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol 125: 312–317

2. Amaravadi R, Schuchter LM, McDermott DF, Kramer A, Giles L, Troxel AB, Medina CA, Nathanson KL, O’Dwyer PJ, Flaherty KT (2007) Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 25: (2007 ASCO Annual Meeting Proceedings Part I, June 20 Supplement) 8527

3. American Cancer Society (2010) Cancer facts and figures 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf . Accessed 17 May 2011

4. Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635–3648

5. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, Deconti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG (2006) Bcl-2 Antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738–4745

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives;Life Sciences;2024-05

2. The action and resistance mechanisms of Lenvatinib in liver cancer;Molecular Carcinogenesis;2023-09-06

3. Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment;Journal of Translational Medicine;2022-02-02

4. Treating Metastatic Brain Cancers With Stem Cells;Frontiers in Molecular Neuroscience;2021-11-24

5. Hypoxia-dependent drivers of melanoma progression;Journal of Experimental & Clinical Cancer Research;2021-05-08